Guinea-Bissau Suspends US-Funded Vaccine Study Amid Controversy Over Human Trial Ethics
In a move that has sent shockwaves through the global health community, Guinea-Bissau's Ministry of Health has suspended a highly-debated US-funded vaccine study on hepatitis B vaccination in infants. The decision comes amid concerns over the ethics of conducting human trials in a country with one of the lowest healthcare standards in the world.
The study, led by Danish researchers and backed by the US Department of Health and Human Services (HHS), was initially given the green light for approval by Guinea-Bissau's ethics committee. However, major changes to the trial design raised red flags among health experts, who accused the researchers of trying to use children as "lab rats" to test the vaccine.
The controversy centered on the fact that some infants would be withheld from vaccination at birth, while others would receive standard doses. The World Health Organization recommends giving all newborns within 24 hours of birth, yet Guinea-Bissau's current healthcare system struggles to meet this basic standard.
Critics argue that the study design is unethical and puts children's lives at risk. "This is not acceptable," said Dr Abdulhammad Babatunde, a medical doctor and global health researcher in Nigeria. "The control group should get the standard of care, and the intervention group should receive potentially better care."
The US HHS had also questioned the credibility of Guinea-Bissau's health officials, labeling the Africa Centres for Disease Control (Africa CDC) as "a powerless, fake organization" trying to manufacture credibility.
However, Dr Jean Kaseya, director-general of the Africa CDC, vehemently defended his organization and its role in responding to outbreaks with global implications. He insisted that the decision to halt the trial was made by Guinea-Bissau's Ministry of Health and that it is "the sovereignty of the country."
The move has sparked outrage among health advocates, who argue that such research should be conducted in a more responsible manner. "It's very important to fund research that Africans actually want," said Dr Babatunde.
Gavin Yamey, professor of global health at the Duke Global Health Institute, echoed similar sentiments, stating that Guinea-Bissau's Ministry of Health is responsible for protecting its citizens' health. "Hearing from ministry officials today is hugely important."
The suspension of the study raises questions about the ethics of conducting human trials in low-resource settings and the need for greater transparency and accountability among researchers.
In a move that has sent shockwaves through the global health community, Guinea-Bissau's Ministry of Health has suspended a highly-debated US-funded vaccine study on hepatitis B vaccination in infants. The decision comes amid concerns over the ethics of conducting human trials in a country with one of the lowest healthcare standards in the world.
The study, led by Danish researchers and backed by the US Department of Health and Human Services (HHS), was initially given the green light for approval by Guinea-Bissau's ethics committee. However, major changes to the trial design raised red flags among health experts, who accused the researchers of trying to use children as "lab rats" to test the vaccine.
The controversy centered on the fact that some infants would be withheld from vaccination at birth, while others would receive standard doses. The World Health Organization recommends giving all newborns within 24 hours of birth, yet Guinea-Bissau's current healthcare system struggles to meet this basic standard.
Critics argue that the study design is unethical and puts children's lives at risk. "This is not acceptable," said Dr Abdulhammad Babatunde, a medical doctor and global health researcher in Nigeria. "The control group should get the standard of care, and the intervention group should receive potentially better care."
The US HHS had also questioned the credibility of Guinea-Bissau's health officials, labeling the Africa Centres for Disease Control (Africa CDC) as "a powerless, fake organization" trying to manufacture credibility.
However, Dr Jean Kaseya, director-general of the Africa CDC, vehemently defended his organization and its role in responding to outbreaks with global implications. He insisted that the decision to halt the trial was made by Guinea-Bissau's Ministry of Health and that it is "the sovereignty of the country."
The move has sparked outrage among health advocates, who argue that such research should be conducted in a more responsible manner. "It's very important to fund research that Africans actually want," said Dr Babatunde.
Gavin Yamey, professor of global health at the Duke Global Health Institute, echoed similar sentiments, stating that Guinea-Bissau's Ministry of Health is responsible for protecting its citizens' health. "Hearing from ministry officials today is hugely important."
The suspension of the study raises questions about the ethics of conducting human trials in low-resource settings and the need for greater transparency and accountability among researchers.